Compounded tirzepatide and 70-lb weight loss: what the evidence says

What did @bertajeanm actually say?

The creator used this clip to do one thing: correct the record. She stated plainly, "I am not on Ozempic. I'm on Monjaro, okay?" The video caption adds more context, noting she's on compounded tirzepatide at 5 mg, with 70 pounds lost since February 25th, combined with weight training. The spoken clip appears to be from a show or interview, where she addresses audience comments suggesting her weight loss was due to Ozempic and that her "head is too big" for her body post-loss. She also mentions having "so much energy" while on the medication. The distinction between tirzepatide (Mounjaro/Zepbound) and semaglutide (Ozempic/Wegovy) matters clinically, and she's right to make it. Conflating all GLP-1 medications into "Ozempic" is one of the most persistent errors in public conversation about weight loss drugs right now.

Does the science back this up?

On the core claim, yes. Tirzepatide and semaglutide are genuinely different drugs with different mechanisms and different outcome data. Tirzepatide is a dual GIP and GLP-1 receptor agonist, while semaglutide is a GLP-1 receptor agonist only. That distinction is not trivial. The SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM) found tirzepatide at its highest dose produced mean weight loss of around 22.5% of body weight in adults with obesity. The STEP 1 trial for semaglutide (Wilding et al., 2021, NEJM) showed roughly 14.9% mean weight loss. The energy claim is harder to evaluate but not implausible. Some patients report improved energy as metabolic function improves with weight loss, though the drug itself is not a stimulant and this is not a documented pharmacological effect of tirzepatide specifically.

What did they get wrong (or right)?

She got the drug distinction right. Tirzepatide is not semaglutide, and calling everything "Ozempic" muddies public understanding of how these therapies work. Credit where it's due. However, the caption references "compounded tirzepatide," which is where things get more complicated. Compounded tirzepatide is not the same as brand-name Mounjaro or Zepbound. Compounded versions are not FDA-approved, have not undergone the same manufacturing standards verification, and the FDA has issued warnings about compounded tirzepatide products specifically. Saying you're on "Monjaro" in the clip while the caption says "compounded tirzepatide" creates a conflation the viewer should notice. She did not explicitly claim the two are equivalent, but the interchangeable framing could mislead followers into assuming compounded versions carry the same safety and efficacy data as the brand-name product. They do not.

What should you actually know?

A few things worth keeping straight. First, 70 pounds of weight loss over roughly five months is a significant result, but individual outcomes vary widely and are influenced by starting weight, adherence, diet, and exercise. She mentions weight training alongside the medication, which is worth noting because GLP-1 class drugs can contribute to muscle loss alongside fat loss. Resistance training during treatment is consistently recommended by clinicians for this reason (Wharton et al., 2023, Obesity Reviews). Second, compounded tirzepatide remains a legally and medically gray area. The FDA removed tirzepatide from its drug shortage list in late 2024, which has regulatory implications for compounders. Anyone considering this route should verify their provider's legitimacy and compounding pharmacy's accreditation. Third, the energy improvement she describes is real for many patients, likely driven by improved insulin sensitivity and reduced metabolic load rather than any direct stimulant effect of the drug itself.

The bottom line

@bertajeanm is making a legitimate and important correction: not all weight loss medications are Ozempic, and tirzepatide's mechanism and outcome data differ from semaglutide's. That part is accurate. The 70-pound result over about five months, combined with weight training, is plausible and consistent with published trial data, though it sits at the higher end of typical outcomes. The area that deserves scrutiny is the compounded versus brand-name framing. These are not interchangeable products, and followers shouldn't assume a compounded tirzepatide product carries the same regulatory standing as Mounjaro or Zepbound. That's not a knock on her experience, it's just a gap in how the information is packaged for a general audience.